LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...

A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...